Blueprint Medicines Corporation (LON:0HOJ)
London flag London · Delayed Price · Currency is GBP · Price in USD
129.31
+0.02 (0.01%)
At close: Jul 11, 2025

Blueprint Medicines Revenue

Blueprint Medicines had revenue of $149.41M USD in the quarter ending March 31, 2025, with 55.45% growth. This brings the company's revenue in the last twelve months to $562.12M, up 99.19% year-over-year. In the year 2024, Blueprint Medicines had annual revenue of $508.82M with 104.04% growth.

Revenue (ttm)
$562.12M
Revenue Growth
+99.19%
P/S Ratio
14.25
Revenue / Employee
$866.13K
Employees
649
Market Cap
6.20B GBP

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End Revenue Change Growth
Dec 31, 2024 508.82M 259.44M 104.04%
Dec 31, 2023 249.38M 45.34M 22.22%
Dec 31, 2022 204.04M 23.96M 13.30%
Dec 31, 2021 180.08M -613.66M -77.31%
Dec 31, 2020 793.74M 727.22M 1,093.37%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
AstraZeneca 42.56B
GSK plc 31.53B
Haleon 11.23B
Smith & Nephew 4.64B
ConvaTec Group 1.83B
Hikma Pharmaceuticals 2.50B
HUTCHMED (China) 503.39M
Oxford Nanopore Technologies 183.19M
Revenue Rankings

Blueprint Medicines News

More News